Chemical structure of Pemigatinib Incyte FGFR1/2/3 kinase inhibitor

oral FGFR1/2/3 kinase inhibitor

approved in oncology, 13.5 mg QD (14d+, 7d-)

from focused screen of ~20k cmpds and SBDD

Journal of Medicinal Chemistry

Incyte Corporation, Wilmington, US

The Incyte FGFR1/2/3 kinase inhibitor, pemigatinib, is an oral kinase inhibitor that obtained an FDA accelerated approval in 2020 for adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma (bile duct cancer) with…

 this content is exclusive to
Premium members

Unlock this content with a Premium membership to read it now.